Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant and Adjuvant Nivolumab +/- Ipilimumab in Stage III Melanoma
NCT04013854Phase 2Active, not recruiting
- Sponsor
- Abramson Cancer Center
- Start
- Jan 2020
- Primary completion
- Oct 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nivolumab and ipilimumab in melanoma (3 arms), sponsored by Abramson Cancer Center. Primary endpoint: Recurrence-Free Survival at 1 year. Started Jan 2020; status: active, not recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04013854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04013854.